Athira Pharma, Inc. ( (ATHA) ) has released its Q1 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors.
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, operating primarily in the biotechnology sector. In its latest earnings report, Athira Pharma highlighted a significant reduction in operating expenses and net loss compared to the previous year, reflecting strategic cost management efforts. Key financial metrics showed a decrease in research and development expenses from $21.2 million to $4.3 million, and a reduction in net loss from $26.3 million to $9.1 million year-over-year. The company reported cash, cash equivalents, and investments totaling $36.7 million as of March 31, 2025, indicating a stable financial position to support ongoing operations. Looking ahead, Athira Pharma remains focused on advancing its pipeline, particularly the development of ATH-1105, while continuing to manage its resources effectively to achieve long-term growth and sustainability.